A sharp profit drop
According to Tuesday's results, Cipla's consolidated net profit for the quarter ended September 30 plunged 35% to 8.78 billion rupees, about $92.2 million, from 13.51 billion rupees a year earlier. Analysts had expected 9.42 billion rupees, according to data compiled by LSEG.
Revenue from operations fell 2.4% to 74.04 billion rupees, partly due to a reclassification from April 1, 2026, under which certain marketing and promotional expenses are now presented as a reduction from revenue rather than under other expenses. The company said the change had no impact on profit or cash flows. Cipla shares fell as much as 2.7% to 1,319 rupees, while the pharma index rose 1.9%.
According to Cipla, the reclassification of certain marketing and promotional expenses had no impact on profit or cash flows. – Cipla
The US slows, India grows
Cipla, India's third-largest drugmaker by revenue, has seen weakness in North America, its biggest overseas market, since the start of the year. The main reason is moderating sales of generic Revlimid, Bristol Myers Squibb's blood cancer drug, after it went off patent.
















